Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70012 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Nathan Martin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb, Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Antigens, CD19, Biological Products, Immunotherapy, Adoptive, Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol Myers Squibb, Bristol-Myers Squibb Canada.
Abstract (Originalsprache)
Idecabtagene vicleucel (ide‐cel), a B‐cell maturation antigen (BCMA)‐directed autologous chimeric antigen receptor (CAR) T‐cell therapy, was studied in relapsed and refractory multiple myeloma after >4 prior lines of therapy in KarMMa (NCT03361748). Translational analyses evaluated patient baseline, tumour and CAR T‐cell features associated with initiating and sustaining response to a single ide‐cel infusion. Baseline tumour burden, measured by soluble BCMA, and homeostatic cytokine levels released after lymphodepleting chemotherapy were among the top correlates for pharmacodynamic response. Duration of response was associated with tumour genomic features and quality of engraftment indicated by more robust CD4+ CAR T‐cell expansion, higher levels of persistent ide‐cel and sustained suppression of BCMA‐expressing cells. A working model is proposed whereby patient and microenvironment features that may modulate ide‐cel activation and expansion influence the probability of response initiation, and that tumour‐intrinsic resistance features and sustained engraftment of ide‐cel influence the durability of responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bristol Myers Squibb, Princeton, New Jersey, USA.
- 2seventy bio, Cambridge, Massachusetts, USA.
- Cancer Center Clínica Universidad de Navarra (CCUN), Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), CIBER-ONC Number CB16/12/00369, Pamplona, Spain.
- Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Nathan Martin, Bruno Paiva
Förderung
- Bristol Myers Squibb
- Bristol-Myers Squibb Canada
Zitieren
APA
Martin, N., Thompson, E., Stong, N., Xu, Y., Finney, O., Rytlewski, J., Flynt, E., Marfo, J., Descalzi-Montoya, D. B., Manrique, I., Paiva, B., Munshi, N., Campbell, T. B., & Kaiser, S. M. (2025). Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/bjh.70012
Vancouver
Martin N, Thompson E, Stong N, Xu Y, Finney O, Rytlewski J, et al. Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma. British Journal of Haematology. 2025. doi:10.1111/bjh.70012
BibTeX
@article{Martin2025,
author = {Martin, Nathan and Thompson, Ethan and Stong, Nicholas and Xu, Yang and Finney, Olivia and Rytlewski, Julie and Flynt, Erin and Marfo, Jessica and Descalzi-Montoya, Dante B and Manrique, Irene and Paiva, Bruno and Munshi, Nikhil and Campbell, Timothy B and Kaiser, Shari M},
title = {Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70012}
}
EUVIMED